ExodusPoint Capital Management’s Motive Capital Corp II Units, each consisting of one Class A ordinary share, and one-third of one redeemable warrant MTVC.U Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-104,802
Closed -$1.07M 2657
2022
Q1
$1.07M Hold
104,802
0.01% 1104
2021
Q4
$1.04M Buy
+104,802
New +$1.05M 0.01% 1046

Other funds holding MTVC.U

ExodusPoint Capital Management's MTVC.U Position: Q2 2022 in Review

ExodusPoint Capital Management sold out of Motive Capital Corp II Units, each consisting of one Class A ordinary share, and one-third of one redeemable warrant (MTVC.U) in Q2 2022, closing a stake of 104,802 shares — an estimated $1.07M sold.

ExodusPoint Capital Management first reported a position in MTVC.U in Q4 2021 and held it in 2 quarters. The position peaked at $1.07M in Q1 2022. 26 funds tracked by Wall St. Rank hold MTVC.U as of Q2 2022.

  • ExodusPoint Capital Management reported no remaining Motive Capital Corp II Units, each consisting of one Class A ordinary share, and one-third of one redeemable warrant position as of Q2 2022 after selling out during the quarter.
  • ExodusPoint Capital Management sold 104,802 Motive Capital Corp II Units, each consisting of one Class A ordinary share, and one-third of one redeemable warrant shares in Q2 2022, an estimated $1.07M.
  • ExodusPoint Capital Management first reported a position in Motive Capital Corp II Units, each consisting of one Class A ordinary share, and one-third of one redeemable warrant in Q4 2021 and held it in 2 quarters.
  • ExodusPoint Capital Management's Motive Capital Corp II Units, each consisting of one Class A ordinary share, and one-third of one redeemable warrant position peaked at $1.07M in Q1 2022.
  • 26 funds tracked by Wall St. Rank held Motive Capital Corp II Units, each consisting of one Class A ordinary share, and one-third of one redeemable warrant as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.